ndacaterol + Mometasone

Glenmark launches Indacaterol + Mometasone FDC for Asthma

Glenmark launches Indacaterol + Mometasone FDC for Asthma

Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily. Alok Malik, Group Vice-President & Head, India Formulations, Glenmark Pharmaceuticals Limited, said, “We are proud to introduce this novel fixed-dose combination Indamet, which is the first…
Read More